Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France

Withdrawn

• Conditions: Self-administered Questionnaire to Patients

• Registration Number: NCT01238809
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to assess in general population low-dose aspirin and gastroprotective agent compliance and reasons for bad compliance

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-11-09
• Study First Submitted QC: 2010-11-09
• Study First Posted: 2010-11-11
• Status Verified: 2011-06
• Study Start: 2011-06
• Last Update Submitted: 2011-06-06
• Last Update Posted: 2011-06-08
• Primary Completion: 2011-07
• Study Completion: 2011-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 7300

Inclusion Criteria

• French people > 60 years old, part of Kantar Health Access Sant� panel

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
low-dose aspirin and gastroprotective treatment compliance (Girerd questionnaire: a 6-item self-administered and validated questionnaire to evaluate adherence to treatments)	One month